166 related articles for article (PubMed ID: 37486460)
41. Nucleolin Promotes Cisplatin Resistance in Cervical Cancer by the YB1-MDR1 Pathway.
Ke J; Gu C; Zhang H; Liu Y; Zhang W; Rao H; Li S; Wu F
J Oncol; 2021; 2021():9992218. PubMed ID: 33976698
[TBL] [Abstract][Full Text] [Related]
42. Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles.
Balinsky CA; Schmeisser H; Ganesan S; Singh K; Pierson TC; Zoon KC
J Virol; 2013 Dec; 87(24):13094-106. PubMed ID: 24027323
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA Profiling of Transgenic Mice with Myocardial Overexpression of Nucleolin.
Lyu QL; Jiang BM; Zhou B; Sun L; Tong ZY; Li YB; Tang YT; Sun H; Liu MD; Xiao XZ
Chin Med J (Engl); 2018 Feb; 131(3):339-346. PubMed ID: 29363650
[TBL] [Abstract][Full Text] [Related]
44. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
45. A Non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer.
Liu Y; Hu B; Pei X; Li J; Qi D; Xu Y; Ou H; Wu Y; Xue L; Huang JH; Wu E; Hu X
Adv Healthc Mater; 2023 Aug; 12(20):e2300791. PubMed ID: 37262080
[TBL] [Abstract][Full Text] [Related]
46. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
47. p85α promotes nucleolin transcription and subsequently enhances EGFR mRNA stability and EGF-induced malignant cellular transformation.
Xie Q; Guo X; Gu J; Zhang L; Jin H; Huang H; Li J; Huang C
Oncotarget; 2016 Mar; 7(13):16636-49. PubMed ID: 26918608
[TBL] [Abstract][Full Text] [Related]
48. Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.
Marcel V; Catez F; Berger CM; Perrial E; Plesa A; Thomas X; Mattei E; Hayette S; Saintigny P; Bouvet P; Diaz JJ; Dumontet C
PLoS One; 2017; 12(1):e0170160. PubMed ID: 28103300
[TBL] [Abstract][Full Text] [Related]
49. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
[TBL] [Abstract][Full Text] [Related]
50. Nuclear Functions of Nucleolin through Global Proteomics and Interactomic Approaches.
Salvetti A; Couté Y; Epstein A; Arata L; Kraut A; Navratil V; Bouvet P; Greco A
J Proteome Res; 2016 May; 15(5):1659-69. PubMed ID: 27049334
[TBL] [Abstract][Full Text] [Related]
51. Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
Merino VF; Yan Y; Ordonez AA; Bullen CK; Lee A; Saeki H; Ray K; Huang T; Jain SK; Pomper MG
Antiviral Res; 2023 Mar; 211():105550. PubMed ID: 36740097
[TBL] [Abstract][Full Text] [Related]
52. Overexpression of SORCIN is a Prognostic Biomarker for Multidrug-Resistant Pediatric Acute Lymphoblastic Leukemia and Correlates with Upregulated MDR1/P-gp.
Dabaghi M; Rahgozar S; Moshtaghian J; Moafi A; Abedi M; Pourabutaleb E
Genet Test Mol Biomarkers; 2016 Sep; 20(9):516-21. PubMed ID: 27382961
[TBL] [Abstract][Full Text] [Related]
53. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma.
Lin Q; Ma X; Hu S; Li R; Wei X; Han B; Ma Y; Liu P; Pang Y
Cancer Manag Res; 2021; 13():1955-1965. PubMed ID: 33658856
[TBL] [Abstract][Full Text] [Related]
55. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
[TBL] [Abstract][Full Text] [Related]
56. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.
Park E; Gang EJ; Hsieh YT; Schaefer P; Chae S; Klemm L; Huantes S; Loh M; Conway EM; Kang ES; Hoe Koo H; Hofmann WK; Heisterkamp N; Pelus L; Keerthivasan G; Crispino J; Kahn M; Müschen M; Kim YM
Blood; 2011 Aug; 118(8):2191-9. PubMed ID: 21715311
[TBL] [Abstract][Full Text] [Related]
57. [Effect of Nucleolin on Lymphoma Proliferation by Regulating Thymidine Kinase 1].
Mei XQ; Hu JD; Yang T; Wu AY; Xu YH; Lin ZH; Lin CM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):699-706. PubMed ID: 37356929
[TBL] [Abstract][Full Text] [Related]
58. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.
Matherly LH; Taub JW; Wong SC; Simpson PM; Ekizian R; Buck S; Williamson M; Amylon M; Pullen J; Camitta B; Ravindranath Y
Blood; 1997 Jul; 90(2):578-89. PubMed ID: 9226157
[TBL] [Abstract][Full Text] [Related]
59. Nucleolin and nucleophosmin expression in seminomas and non-seminomatous testicular tumors.
Masiuk M; Lewandowska M; Teresinski L; Dobak E; Urasinska E
Folia Histochem Cytobiol; 2019; 57(3):139-145. PubMed ID: 31513277
[TBL] [Abstract][Full Text] [Related]
60. Nucleolin as a potential biomarker for canine malignant neoplasia.
Cruz C; Pedro AQ; Carvalho J; Santos T; Talhada D; Paiva A; Queiroz JA; Andrade M; Pinto M; Montenegro L; Delgado L; Pereira P
Res Vet Sci; 2021 Mar; 135():297-303. PubMed ID: 33077166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
